Nasdaq

Cognition Therapeutics Announces Expanded Access Program for Dementia with Lewy Bodies, Led by Dr. James Galvin

Cognition Therapeutics, Inc. announced the initiation of an expanded access program (EAP) funded by an anonymous philanthropic donation from the family of a patient with dementia with Lewy bodies (DLB ...
Nasdaq

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...
Benzinga.com

Armed With Donation From Trial Participant's Family, Cognition (Nasdaq: CGTX) Initiates Expanded Access Program For Experimental DLB Drug

Cognition Therapeutics Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders including Dementia with Lewy Bodies (DLB), just received assistance in those ...

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a second philanthropic ...
Hosted on MSN

Cognition reaches full enrollment in expanded access program for CT1812

Cognition Therapeutics (CGTX) announced that its expanded access program has reached full enrollment. Each of the individuals enrolled in the program are being treated with 100 mg of oral zervimesine ...
Mena FN

Cognition Therapeutics Receives Second Philanthropic Donation To Extend Ongoing Expanded Access Program For Zervimesine (CT1812) In Dementia With Lewy Bodies

(MENAFN- GlobeNewsWire - Nasdaq) PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the“Company” or“Cognition”) (NASDAQ: CGTX), a ...